Reuters – German drugs and healthcare group Merck KGaA is in talks with external investors including private equity firms to share the cost of some clinical trials, the Financial Times said, citing a senior manager at the company.
The diversified group is also exploring more “risk-sharing” deals under which the company would receive a fee linked to the success of some of its products including in-vitro fertility treatments, the newspaper said on Monday, citing Stefan Oschmann, executive board member.
The newspaper cited Oschmann as saying that a late-state trial for a cancer drug typically costs between 150 million euros ($203 million) and 400 million euros. That cost rises to as much as 600 million euros for multiple sclerosis drugs, he said. ($1=0.7373 euros) (Reporting by Maria Sheahan; Editing by Greg Mahlich)